BMRN Q3 2017 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$334M+19.4% YoY

Gross Profit

$275M82.2% margin

Operating Income

-$14M-4.1% margin

Net Income

-$13M-3.7% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+5.3%

Cash Flow

Operating Cash Flow

$38M

Free Cash Flow

-$4M

Stock-Based Comp.

$36M

Balance Sheet

Total Assets

$4.6B

Total Liabilities

$1.8B

Stockholders' Equity

$2.8B

Cash & Equivalents

$431M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$334M	$280M	+19.4%
Gross Profit	$275M	$229M	+19.9%
Operating Income	-$14M	-$60M	+77.2%
Net Income	-$13M	-$37M	+66.5%

Revenue Segments

Product Five

$5M100%

Geographic Segments

UNITED STATES

$151M45%

Europe

$98M29%

Rest Of World

$59M18%

Latin America

$26M8%